Dr Secord sits down with ecancer to discuss the data she presented at ESMO 2024 from the phase 3 PICCOLO trial in pretreated ovarian cancer.

The antibody-drug conjugate mirvetuximab soravtansine-gynx achieved a 51.9% objective response rate (ORR) and a median duration of response (DOR) of 8.25 months in patients with folate receptor–alpha (FRα)-positive, platinum-sensitive ovarian cancer who were heavily pretreated.

The results met both primary and secondary endpoints and full trial results will be presented at a future medical meeting. The safety profile was consistent with previous findings.

Dr Secord noted the need for new treatments in this area, as current therapies for platinum-sensitive ovarian cancer lose effectiveness over time.

The FDA recently fully approved mirvetuximab soravtansine for FRα-positive, platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer, based on the phase 3 MIRASOL trial, which demonstrated improvements in survival compared to chemotherapy.